Publications
Find coverage of the latest original articles on Lupus, focusing on those with data on therapeutic interventions and those that have clinical impact.
December 2025
Anti-CD38 monoclonal antibody CM313 for systemic lupus erythematosus: A randomized, double-blind, placebo-controlled Phase Ib/IIa trial
Signal Transduct Target Ther 2025;10:383 Doi: 10.1038/s41392-025-02487-2
Zhao et al. showed that CM313 was well tolerated in adult patients with SLE at doses of 2–16mg/kg and showed encouraging pharmacodynamic effects and preliminary efficacy at doses of 8 and 16 mg/kg QW. CM313 also produced dose-dependent and clinically meaningful improvements in key serological biomarkers of SLE.
Predictors of damage accrual by organ domain in systemic lupus erythematosus
Rheumatology 2025;18:keaf610 Doi: 10.1093/rheumatology/keaf610 Epub ahead of print
Kandane-Rathnayake et al. reported that risk factors for individual organ system damage were highly varied in patients with SLE, and not all factors associated with domain-specific damage were captured by summed systemic lupus international collaborating clinics/american college of rheumatology damage index (SLICC/ACR SDI) for overall organ damage.